NSF PD 19-125Y - Science of Science: Discovery, Communication, and Impact (SoS:DCI) -Randomized Control Trial of the Registered Reports Publishing Format
NSF PD 19-125Y - Science of Science: Discovery, Communication, and Impact (SoS:DCI) -Randomized Control Trial of the Registered Reports Publishing Format
批准号:
2152424
负责人:
Brian Nosek
金额:
$75.0万
依托单位:
依托单位国家:
美国
项目类别:
Continuing Grant
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-01 至 2026-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Registered Reports (RR) publishing model could be transformative to how research is conducted, peer reviewed, and published. RRs could alter incentives for researchers toward focusing on asking important questions and using strong methodology to test those questions, and away from the demand for exciting, provocative results whatever their credibility. Ultimately, RRs can improve the quality of peer review and scholarly communication, thus improving the rigor, transparency, and reproducibility of research. Large-scale adoption of RRs could fundamentally change how research is evaluated and communicated.In a RR, authors submit a paper detailing the research question and proposed methodology to test the question prior to observing the study outcomes. In the first stage of peer review, reviewers assess the importance of the question and the quality of the methodology proposed to investigate it. If the paper passes this stage of peer review, the authors receive “in-principle acceptance” meaning that the journal commits to publishing the paper regardless of outcomes as long as the authors follow through with competent execution and reporting of the research. The second stage of peer review, after the results are known and added to the paper, assesses adherence to the original commitments, clarity of the distinction between planned and unplanned analyses, and accuracy of interpretation of findings, and not whether the results are positive, interesting, or consistent with hypotheses. Given the potentially transformative impact of RRs on the research process, it is essential to conduct a randomized trial to evaluate the model’s qualities. By collaborating with journals, we will conduct a randomized trial of RRs in an ecologically valid context.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Collaborative Research: CCRI: ENS: Boa 2.0: Enhancing Infrastructure for Studying Software and its Evolution at a Large Scale
-
批准号:2120345
-
项目类别:Standard Grant
-
资助金额:$22.74万
-
财政年份:2021
-
负责人:Brian Nosek
-
依托单位:
Ethical and Responsible Research (ER2) Rigor and Transparency Initiatives (RTI)
-
批准号:2023403
-
项目类别:Standard Grant
-
资助金额:$63.98万
-
财政年份:2020
-
负责人:Brian Nosek
-
依托单位:
EAGER: Community Building and Workflows for Data Sharing with Publicly Accessible and Consumable Metadata
-
批准号:2032650
-
项目类别:Standard Grant
-
资助金额:$29.9万
-
财政年份:2020
-
负责人:Brian Nosek
-
依托单位:
An EHR Core Research (ECR) Data Resource Hub to catalyze culture change and community building for improving rigor and reproducibility in STEM education research
-
批准号:1937698
-
项目类别:Standard Grant
-
资助金额:$99.74万
-
财政年份:2019
-
负责人:Brian Nosek
-
依托单位:
Implicit Cognition in STEM Education
-
批准号:0634041
-
项目类别:Continuing Grant
-
资助金额:$0.0万
-
财政年份:2006
-
负责人:Brian Nosek
-
依托单位:
国内基金
海外基金
登录
查看更多内容
CYP19A1/ALOXE3双重抑制剂重塑免疫微环境增敏结肠癌抗PD-1治疗及机制研究
-
批准号:82373125
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:杨静
-
依托单位:
时空控释PD-L1/CCL19/奥沙利铂纳米粒子改善免疫微环境治疗乳腺癌的机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:
-
依托单位:
MAP3K19通过促进树突状细胞DCs表达PD-L1调控滤泡辅助性Tfh细胞分化影响下咽癌进展的研究
-
批准号:82260547
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:梁进
-
依托单位:
FGF19通过PI3K-Akt-MYC轴上调PD-L1促进肝癌免疫逃逸的机制及其应用研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:周静
-
依托单位:
时空控释PD-L1/CCL19/奥沙利铂纳米粒子治疗骨肉瘤的功能和机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:李劲松
-
依托单位:
lncZEB2-19通过Wnt/Zeb1/PD-L1途径介导微环境促进肝癌免疫逃逸的分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:汪田甜
-
依托单位:
免疫检查点配体PD-L1对CAR-T细胞活性的增强作用及机制研究
-
批准号:82070170
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐颖茜
-
依托单位:
TAMs通过外泌体源LncRNA H19/STAT3/PD-L1通路介导胃癌免疫抑制微环境的机制研究
-
批准号:82003041
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:魏辰
-
依托单位:
基于MITF途径双重下调免疫检查点FGL1和PD-L1的土贝母苷甲类新化合物TBM-19抗肿瘤免疫作用及机制研究
-
批准号:81973366
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:邓洪斌
-
依托单位:
长链非编码RNA CASC19通过调控PD-L1表达与免疫微环境促进胃癌转移的机制研究
-
批准号:81902425
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2019
-
负责人:张洁筠
-
依托单位: